<DOC>
	<DOCNO>NCT01684566</DOCNO>
	<brief_summary>To compare performance standard care ( SOC ) + episil® versus SOC alone oral mucositis patient receive condition treatment hematopoietic stem cell transplantation ( HSCT ) . The primary variable area curve ( AUC ) oral mucositis score define World Health Organisation ( WHO ) oral toxicity scale assess daily investigator 28-day study period .</brief_summary>
	<brief_title>A Comparative Investigation Standard Of Care ( SOC ) Episil® Combination Versus SOC Alone Oral Mucositis</brief_title>
	<detailed_description>This multicentre , open-label , randomise parallel-group study . Patients randomise one two parallel treatment group : episil® combination SOC SOC alone . The study originally plan conduct several site follow country : Denmark , Israel , Poland , Sweden . Following country-specific Amendment 20-Feb-2013 German Ethical Committee ( EC ) approval 07-May-2013 , Germany add list country study would conduct . No study sit initiate Denmark . The study design aim facilitate direct comparison performance SOC + episil® versus SOC alone . The study conduct open-label manner common trial involve cancer patient , take account ethical issue involve indication patient population . To reduce likelihood bias , assignment study treatment randomise . SOC control group appropriate widely use , especially trial involve cancer patient . In particular study , basic oral hygiene consist brushing , flossing , rinse moisturise take SOC use control group .</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>1 . Is least 18 year age . 2 . Has confirm diagnosis he/she schedule hematopoietic stem cell transplantation ( HSCT ) either type transplant ( autologous allogeneic ) . 3 . Is due undergo treatment myeloablative conditioning ( radiationbased non radiation base ) HSCT . 1 . Will undergo reduce intensity conditioning HSCT . 2 . Has get know allergy ingredient study product peanut , peppermint oil , soya . 3 . Is pregnant breast feeding . 4 . Has concurrent medical condition , opinion investigator , would increase risk patient , compromise evaluation investigational device , interfere conduct study . 5 . Has unstable condition ( eg , psychiatric disorder , recent history substance abuse ) otherwise think unreliable incapable complying study requirement . 6 . Is undergoing treatment parenteral opioids enrolment . 7 . Uses treatment promote mucosal healing ( eg , palifermin ) . 8 . Uses electrolyte mouthwash ( eg , Caphosol® ) topical oral treatment ( eg , Tantum Verde® ( benzydamine ) , Gelclair® , Fungicidin ( nystatin ) ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>